Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Performance of GPT‐4o in the management of toxicological exposures: A comparative analysis with emergency medicine residents
0
Zitationen
6
Autoren
2025
Jahr
Abstract
Abstract Background Timely decision‐making is critical for managing toxicological exposures; however, many physicians lack toxicology‐specific experience and resources. Objectives This study aimed to assess whether GPT‐4o, an artificial intelligence (AI)‐based decision support system, could provide emergency medicine residents with information for managing toxicology cases and to analyze its potential effectiveness in guiding treatment decisions compared to toxicologists. Methods We conducted a prospective observational study with 30 emergency medicine residents (16 junior residents [JRs] and 14 senior residents [SRs]) using GPT‐4o. Each resident was assigned 30 clinical scenarios derived from real‐life toxicological exposure cases. GPT‐4o responded to the same 30 scenarios assigned to each resident. The responses from the residents and GPT‐4o were compared to gold standard (GS) responses determined by a medical toxicologist. Cohen's kappa coefficient was used to evaluate the agreement between each group's responses and the GS. Results GPT‐4o and SRs showed a similar and good agreement with the GS for recommending antidotal treatment (GPT‐4o: κ = 0.710, p < 0.001; SR: κ = 0.704, p < 0.001). This agreement was lower among JRs ( κ = 0.451, p < 0.001). Regarding the recommendation for enhancing elimination treatment, GPT‐4o demonstrated greater agreement with the GS ( κ = 0.632, p < 0.001) than SRs ( κ = 0.551, p < 0.001) and JRs ( κ = 0.293, p < 0.001). Conclusions Although ChatGPT‐4o demonstrated good agreement with the medical toxicologist, the observed risk of incorrect recommendations suggests that AI‐based systems should currently be considered as supportive tools rather than stand‐alone decision makers. Expert toxicological oversight remains important, particularly for high‐stakes clinical decisions.
Ähnliche Arbeiten
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 · 33.647 Zit.
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
2020 · 18.531 Zit.
To Err Is Human
2000 · 14.076 Zit.
Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
2007 · 9.570 Zit.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
2024 · 6.841 Zit.